NasdaqGS:GLUEBiotechs
Does Early MRT-2359 Data And Insider Selling Shift The Bull Case For Monte Rosa (GLUE)?
In May 2026, Monte Rosa Therapeutics reported encouraging Phase 1/2 data for MRT-2359 in metastatic castration-resistant prostate cancer and shared new preclinical findings for MRT-55811 showing tumor regression across several cancer models.
At the same time, director Anthony M. Manning exercised options and sold US$180,100 of stock, a routine move that contrasts with the company’s recent scientific progress.
Next, we’ll examine how these early-stage oncology results, especially the...